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Should Nondiabetic Patients With 3-Vessel Disease and Stable Ischemic Heart Disease
Be Preferentially Treated With CABG?1647Pranav Kansara, Sandra Weiss, William S. Weintraub, Matthew C. Hann, James Tcheng,
S. Tanveer Rab, Lloyd W. Klein, on behalf of the Interventional Council of
the American College of CardiologyCLINICAL RESEARCH
CORONARY Comparative Effectiveness and Safety of New-Generation Versus
Early-Generation Drug-Eluting Stents According to Complexity of
Coronary Artery Disease: A Patient-Level Pooled Analysis of 6,081 Patients1657Raffaele Piccolo, Thomas Pilgrim, Dik Heg, Anna Franzone, Julie Rat-Wirtzler,
Lorenz Räber, Sigmund Silber, Patrick W. Serruys, Peter Jüni, Stephan WindeckerThis study compared the safety and effectiveness of new- versus early-generation drug-eluting stents
(DES) according to the complexity of underlying coronary artery disease as assessed by the
angiographic SYNTAX score. Data from 6,081 patients were pooled and outcomes were analyzed at
2-year follow-up. Compared with early-generation DES, new-generation DES reduced the risk of the
primary device-oriented clinical endpoint. Moreover, new-generation DES showed improved
effectiveness (target lesion revascularization) and safety (stent thrombosis) among patients with
SYNTAX score >11. The study demonstrated that the SYNTAX score did not affect the relative
beneﬁts of new- over early-generation DES, which may be more pronounced in patients with
SYNTAX score >11.
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NOVEMBER 2015 VOLUME 8, NUMBER 13Diagnostic and Prognostic Implications of Coronary Flow Capacity:
A Comprehensive Cross-Modality Physiological Concept in Ischemic Heart Disease1670Tim P. van de Hoef, Mauro Echavarría-Pinto, Martijn A. van Lavieren,
Martijn Meuwissen, Patrick W.J.C. Serruys, Jan G.P. Tijssen, Stuart J. Pocock,
Javier Escaned, Jan J. PiekCoronary ﬂow capacity (CFC) comprehensively documents ﬂow impairment in the coronary circulation
by interpreting coronary ﬂow reserve (CFR) in relation to maximal ﬂow (hAPV). After stratiﬁcation in
normal, mildly reduced, moderately reduced, or severely reduced CFC, the diagnostic and prognostic
implications of CFC were evaluated in patients in whom revascularization was deferred. Combining
CFR and hAPV improved the prediction of major adverse cardiac events (MACE) during 11.9 years of
follow-up over CFR alone, and MACE rates throughout follow-up were strongly associated with
advancing impairment of CFC (p ¼ 0.002). CFC is an integrative physiological concept that may
improve risk stratiﬁcation in ischemic heart disease patients.
SEE ADDITIONAL CONTENT ONLINECombining Baseline Distal-to-Aortic Pressure Ratio and Fractional Flow Reserve
in the Assessment of Coronary Stenosis Severity1681Mauro Echavarría-Pinto, Tim P. van de Hoef, Martijn A. van Lavieren, Sukhjinder Nijjer,
Borja Ibañez, Stuart Pocock, Alicia Quirós, Justin Davies, Martijn Meuwissen,
Patrick W. Serruys, Carlos Macaya, Jan J. Piek, Javier EscanedThis study sought to understand the physiological basis of baseline distal-to-aortic pressure ratio
(Pd/Pa) and fractional ﬂow reserve (FFR) agreement and discordance, using intracoronary pressure
and ﬂow measurements. Although Pd/Pa and FFR were closely correlated (r ¼ 0.798; 95%
conﬁdence interval: 0.767 to 0.828), categorical discordance was observed in 19.3% of total
(N ¼ 467) vessels. Such discordance was associated with the patients’ clinical proﬁle and was
characterized by contrastive changes in stenosis resistance, microcirculatory resistance, and the
underlying coronary ﬂow reserve. All stenosis with Pd/Pa #0.83 (n ¼ 74, 15.8%) progressed to
FFR #0.80, and although no Pd/Pa cutoff was able to exclude the development of FFR #0.80 in
the high end of values, only 15 (10.1%) vessels with Pd/Pa $0.96 (n ¼ 149, 31.9%) developed
FFR #0.80, from which none had deﬁnite ischemia, as deﬁned by coronary ﬂow reserve #1.74.
Combining baseline Pd/Pa with FFR seems to provide a more comprehensive physiological
examination of stenosed coronary arteries.
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NOVEMBER 2015 VOLUME 8, NUMBER 13Long-Term Outcomes After Treatment With a Paclitaxel-Coated Balloon Versus Balloon
Angioplasty: Insights From the PEPCAD-DES Study (Treatment of Drug-eluting Stent
[DES] In-Stent Restenosis With SeQuent Please Paclitaxel-Coated Percutaneous
Transluminal Coronary Angioplasty [PTCA] Catheter)1695Harald Rittger, Matthias Waliszewski, Johannes Brachmann,
Wolfgang Hohenforst-Schmidt, Marc Ohlow, Andreas Brugger, Holger Thiele,
Ralf Birkemeyer, Volkhard Kurowski, Christian Schlundt, Stefan Zimmermann,
Sandra Lonke, Moritz von Cranach, Sinisa Markovic, Werner G. Daniel,
Stephan Achenbach, Jochen WöhrleIn the PEPCAD-DES (Treatment of Drug-eluting Stent [DES] In-Stent Restenosis With SeQuent
Please Paclitaxel-Coated Percutaneous Transluminal Coronary Angioplasty [PTCA] Catheter) study,
110 patients with drug-eluting stent in-stent restenosis in native coronary arteries were
randomized to treatment with either paclitaxel-coated balloons (PCBs) or plain old balloon
angioplasty (POBA) in a multicenter, randomized, single-blind trial. At baseline, there were lesions
with at least 2 stent layers in PCB patients (52.8%, 38 of 72) and POBA patients (55.3%, 21 of 38).
The 36-month major adverse cardiac event rate was signiﬁcantly reduced in the PCB group
compared with the POBA group (20.8% vs. 52.6%; p ¼ 0.001). PCB angioplasty was superior to
POBA for the treatment of drug-eluting stent in-stent restenosis patients in terms of major
adverse cardiac events and target lesion revascularization for up to 36 months. There was no late
catch-up phenomenon.n EDITORIAL COMMENT
Paclitaxel-Coated Balloon for Recalcitrant In-Drug-Eluting Stent Restenosis 1701
Julinda Mehilli, David Jochheim
Comparison of Stent Expansion Guided by Optical Coherence Tomography Versus
Intravascular Ultrasound: The ILUMIEN II Study (Observational Study of
Optical Coherence Tomography [OCT] in Patients Undergoing Fractional Flow
Reserve [FFR] and Percutaneous Coronary Intervention)1704Akiko Maehara, Ori Ben-Yehuda, Ziad Ali, William Wijns, Hiram G. Bezerra, Junya Shite,
Philippe Généreux, Melissa Nichols, Paul Jenkins, Bernhard Witzenbichler,
Gary S. Mintz, Gregg W. StoneTo determine whether optical coherence tomography (OCT) and intravascular ultrasound (IVUS)
result in comparable stent expansion, the authors compared the relative degree of stent expansion
after OCT-guided stenting in patients in the ILUMIEN I (Observational Study of Optical Coherence
Tomography [OCT] in Patients Undergoing Fractional Flow Reserve [FFR] and Percutaneous
Coronary Intervention (N ¼ 354) and IVUS-guided stenting from patients in the ADAPT-DES
(Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) study (N ¼ 586). The degree
of stent expansion was not signiﬁcantly different between OCT and IVUS guidance in both
matched-pair and covariate-adjusted analyses. Although OCT detected a higher prevalence of
post–percutaneous coronary intervention stent malapposition, tissue protrusion, and edge
dissections, the rates of major malapposition, tissue protrusion, and dissections were also similar
after OCT- and IVUS-guided stenting.
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NOVEMBER 2015 VOLUME 8, NUMBER 13Relation Between Bioresorbable Scaffold Sizing Using
QCA-Dmax and Clinical Outcomes at 1 Year in 1,232 Patients
From 3 Study Cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II)1715Yuki Ishibashi, Shimpei Nakatani, Yohei Sotomi, Pannipa Suwannasom,
Maik J. Grundeken, Hector M. Garcia-Garcia, Antonio L. Bartorelli, Robert Whitbourn,
Bernard Chevalier, Alexandre Abizaid, John A. Ormiston, Richard J. Rapoza,
Susan Veldhof, Yoshinobu Onuma, Patrick W. SerruysThe relationship between quantitative coronary angiography–maximal lumen diameter (Dmax)
guidance for Absorb scaffold size selection and clinical outcomes is unknown. The incidence of
major adverse cardiac events (MACE) was analyzed in 1,248 patients according to the Dmax
subclassiﬁcation of scaffold oversize group versus nonoversize group. Implantation of an oversized
scaffold in a relatively small vessel appears to be associated with a higher 1-year MACE rate driven
by more frequent early myocardial infarction (MI) (MACE: 6.6% vs. 3.3%; log-rank p < 0.01, all
MI: 4.6% vs. 2.4%; log-rank p ¼ 0.04). The independent MACE determinants were both Dmax
smaller than the scaffold nominal size and overlapping implantation.
SEE ADDITIONAL CONTENT ONLINESTRUCTURAL A Strategy of Underexpansion and Ad Hoc Post-Dilation of
Balloon-Expandable Transcatheter Aortic Valves in Patients at Risk of Annular Injury:
Favorable Mid-Term Outcomes1727John S. Tan, Jonathon Leipsic, Gidon Perlman, Dion Stub, Danny Dvir,
Nicolaj C. Hansson, Bjarne L. Norgaard, Philipp Blanke, Anson Cheung, Jian Ye,
Christopher R. Thompson, Robert R. Moss, Sandra Lauck, David Wood, John WebbThe aim of this study was to evaluate a strategy of underexpanding balloon-expandable transcatheter
aortic valves in patients at risk of annular injury. An optimally sized valve ensures paravalvular sealing
and stability without risking annular injury. However, operators may be forced to choose between a
transcatheter heart valve that is too small or another that is too large. The authors evaluated modest
underexpansion of oversized valves in 47 patients at risk of annular injury out to 1 year. An
underﬁlling strategy appeared safe and effective without compromising valve function or
durability. When oversizing is a concern, a strategy of underexpansion may reduce the risk of annular
injury without compromising valve performance.n EDITORIAL COMMENT
Transcatheter Valve Sizing and the Rigid Aortic Root:
An Ongoing Dilemma to Avoid the Worst1733Vinod H. Thourani, Jessica ForcilloCONTINUED ON PAGE A-34
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NOVEMBER 2015 VOLUME 8, NUMBER 13Transcatheter Aortic and Mitral Valve-in-Valve Implantation for
Failed Surgical Bioprosthetic Valves: An 8-Year Single-Center Experience1735Jian Ye, Anson Cheung, Michael Yamashita, David Wood, Defen Peng, Min Gao,
Christopher R. Thompson, Brad Munt, Robert R. Moss, Philipp Blanke, Jonathon Leipsic,
Danny Dvir, John G. WebbTranscatheter aortic and mitral valve-in-valve (VinV) implantations were successfully performed
for failed bioprostheses in 72 of 73 patients using balloon-expandable transcatheter valves.
Estimated survival rates were 88.9%, 79.5%, 69.8%, 61.9%, and 40.5% at 1, 2, 3, 4, and 5 years,
respectively. The small surgical valve size (19 and 21 mm) was an independent risk factor for
reduced survival in aortic VinV patients. Transcatheter VinV provides encouraging mid-term clinical
outcomes in this high-risk elderly cohort of patients. Transcatheter VinV is an acceptable
alternative therapy for failed aortic or mitral bioprostheses in selected high-risk patients.n EDITORIAL COMMENT
New Ways of Thinking About Senescent Bioprosthetic Heart Valve Therapy 1745
Rakesh M. Suri, Ahmad Edris, Faisal Hasan
Incidence, Causes, and Predictors of Early (#30 Days) and
Late Unplanned Hospital Readmissions After Transcatheter Aortic Valve Replacement1748Luis Nombela-Franco, María del Trigo, Guillermo Morrison-Polo, Gabriela Veiga,
Pilar Jimenez-Quevedo, Omar Abdul-Jawad Altisent, Francisco Campelo-Parada,
Corina Biagioni, Rishi Puri, Robert DeLarochellière, Eric Dumont, Daniel Doyle,
Jean-Michel Paradis, Alicia Quirós, Carlos Almeria, Nieves Gonzalo, Ivan Nuñez-Gil,
Pablo Salinas, Siamak Mohammadi, Javier Escaned, Antonio Fernández-Ortiz,
Carlos Macaya, Josep Rodés-CabauUnplanned readmissions after cardiac interventions are frequent with an impact on outcomes and health
care costs. The present study evaluates the incidence, causes, and predictors of early (#30 days) and late
(>30 days to 1 year) readmissions after transcatheter aortic valve replacement. The readmission
burden within 30-day and 1-year follow-up was high (14.6% and 43.9%, respectively), due to
noncardiac causes in more than one-half of the patients (w60%). Whereas early readmissions were
mainly related to periprocedural bleeding events, most late readmissions were secondary to baseline
patient comorbidities. Early readmission was associated with a higher mortality rate at follow-up.PERIPHERAL Safety and Efﬁcacy of Stent Retrievers for the Management of Acute Ischemic Stroke:
Comprehensive Review and Meta-Analysis1758Konstantinos Marmagkiolis, Abdul Hakeem, Mehmet Cilingiroglu, Betul Gundogdu,
Cezar Iliescu, Despina Tsitlakidou, Angelos KatramadosStroke is a leading cause of death and disability in the United States. Stent retrievers are novel
endovascular devices that provide vessel recanalization via thrombus retrieval mechanical
thrombectomy. Five RCTs (MR CLEAN, ESCAPE, EXTEND-IA, SWIFT-PRIME, and REVASCAT) were
identiﬁed. The frequency of a low 90-day modiﬁed Rankin Score 0 to 2 in the intervention group
was 42.6% compared with 26.1% in the control group. The frequency of intracranial bleeding was
4.2% in the intervention group compared with 4.3% in the control group. The 90-day mortality
was 15.1% in the intervention group compared with 18.7% in the control group.n EDITORIAL COMMENT
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INTERVENTIONVery Late Scaffold Thrombosis Due to Insufﬁcient Strut Apposition 1768
Felix Meincke, Tobias Spangenberg, Christian-H. Heeger, Martin W. Bergmann,
Karl-Heinz Kuck, Alexander Ghanem
Embolization of Left Atrial Appendage Thrombus During
Transcatheter Aortic Valve Replacement: A Potential Mechanism
of Periprocedural Stroke1770Paul D. Williams, Mark A. de Belder, Neil Maredia, Douglas F. Muir
n ONLINE FEATURE Severe Neointimal Hyperplasia of Neoplastic Carina Following
Bioresorbable Scaffold Implantation Using T-Stenting and Small Protrusion Technique:
Insights From Optical Frequency Domain Imaginge207Hiroyoshi Kawamoto, Neil Ruparelia, Filippo Figini, Azeem Latib, Antonio Colombo
n ONLINE FEATURE First-in-Man Implantation of a Tricuspid Annular Remodeling
Device for Functional Tricuspid Regurgitatione211Azeem Latib, Eustachio Agricola, Alberto Pozzoli, Paolo Denti, Maurizio Taramasso,
Pietro Spagnolo, Jean-Michel Juliard, Eric Brochet, Phalla Ou, Maurice Enriquez-Sarano,
Francesco Grigioni, Ottavio Alﬁeri, Alec Vahanian, Antonio Colombo, Francesco Maisano
n ONLINE FEATURE Anterior Mitral Leaﬂet Perforation During
Transcatheter Aortic Valve Replacement in a Patient With Mitral Annular Calciﬁcatione215Mike Saji, Gorav Ailawadi, Michael Ragosta, Dale E. Fowler, John M. Dent, D. Scott Lim
n ONLINE FEATURE Thrombus in the Aorta: Late Complication After
Percutaneous Closure of Ruptured Sinus of Valsalva Aneurysme217Robert Sabiniewicz, Jarosław Meyer-Szary, Piotr Siondalski, Magdalena Kołaczkowska,
Rafał Gała˛ska
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Andrew R. Leventhal, Ashish H. Shah, Andrew M. Crean, Mark Osten, Eric Horlick,
Lee Benson
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From the Left Anterior Descending Artery in a Patient With Anterolateral ST-Segment
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